Weil offers a comprehensive, national IP practice, comprising Patent Litigation, Technology and IP Transactions, IP/Media (which encompasses trademark, copyright, music licensing, privacy, and false advertising matters), and our cross-disciplinary IP Counseling Practice.
Weil’s national Patent Litigation practice offers strong platforms in Silicon Valley, New York, and Washington, DC, with more than 30 practitioners nationally. We have earned a reputation as a go-to firm for high stakes patent litigation in all of the major venues, including in federal district courts, at the United States International Trade Commission, on appeal at the Federal Circuit, or before the Patent Office. Our patent litigators regularly handle matters where the rulings are game-changing and where the law, facts, and technology are complex. In many instances, these cases often have far-reaching impacts across entire industries. Importantly, many of our attorneys have degrees in chemistry, biology, computer science, electrical engineering, mechanical engineering, and physics. These technical and scientific backgrounds allow us to identify critical issues and quickly understand the technology at the forefront of a case. With the majority of our team licensed to practice before the U.S. Patent Office, our team has unique strategic advantages in being able to navigate the interplay of district court cases and IPR/post-grant proceedings. Indeed, our lawyers are leaders in inter partes review and covered business method review proceedings, having handled more than 300 of them since 2012.
Our Technology and IP Transactions group comprises 33 lawyers in New York, Silicon Valley and London who spend 100% of their time on technology and intellectual property transactions—a distinguishing feature of Weil—bringing deep expertise to client matters. We represent our clients in all stages of development, from start-ups to Fortune 50, across a broad range of industries. We are well known for our cutting-edge work across all forms of stand-alone technology and intellectual property transactions such as patent acquisitions, licensing agreements, joint ventures, strategic alliances, research and development collaborations, internet/e-commerce arrangements and other types of cross-border technology transactions.
Our IP/Media practice, which boasts nearly two dozen lawyers with IP expertise and courtroom experience, has a leading reputation for success dealing with and litigating cutting-edge IP issues. Leading social media platforms, digital music streaming companies, major media and entertainment companies, global e-commerce platforms and international financial services companies regularly turn to Weil’s IP/Media practice to manage: cutting-edge secondary liability issues; DMCA safe harbors and compliance requirements; music licensing; trademark and copyright licensing requirements; trademark strategy, enforcement and litigation; IP matters arising in the transactional context; false advertising claims; development of terms of service, fair use and assessment of infringement risks (both direct and secondary); and strategies associated with the clients’ service offerings and product development initiatives. Weil also has the nation’s pre-eminent service-side music copyright practice, and has litigated more than a dozen royalty rate-setting proceedings—far more than any other law firm. We work closely with our broad base of clients to coordinate these issues on a global basis, and over the last several decades, our lawyers have participated in many of the most significant trademark and copyright cases.
Weil’s clients benefit from our deep bench of leading practitioners with the full spectrum of IP capabilities. Clients of the group include: AbbVie; AIG; Alibaba; BASF; BBC Studios; Bio-Rad; Brookfield; CareDx; CBS; Comcast; eBay; Eli Lilly; Getty Images; General Electric; GLOBALFOUNDRIES Inc.; Houghton Mifflin Harcourt; HP, Inc.; Illumina; Intel; Johnson & Johnson; Kroger; Lenovo Group; Meta Platforms; Nuance Communications; Oracle; Pacific Biosciences; Palo Alto Networks; Pandora Media; Regeneron Pharmaceuticals; S&P Global; Samsung; Sanofi; SiriusXM; and Tesla; among others.
